Eivind Hovig

Eivind Hovig is a Professor at the University of Oslo, Norway, coordinating bioinformatics in the Oslo region. He heads a research group at the Norwegian Radium Hospital, also in Oslo, and is responsible for clinical bioinformatics at this institution. His laboratory-based research is within cancer, with a focus on methods development. Several targeted gene silencing techniques have been developed, and are currently being developed for clinical utility. High-throughput genomics technologies have been applied to discern mechanisms involved in the silencing techniques. He has a long standing interest in mutation detection techniques. Hovig also heads a bioinformatics research group, that has pioneered text mining in a genomic context, participated in large scale comparisons of microarray platforms. Recently, the group has opened the research field of human genome denaturation characteristics.

Biography Updated on 2 October 2007

Personal Home Page

http://www.radium.no/hovig/

Articles in Scholarly Journals [Incomplete List]

  1. Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers
    European Journal of Cancer, vol. 43, no. 11, pp. 1713–1717, 2007
  2. Gene Expression Analysis in Blood Cells in Response to Unmodified and 2'-Modified siRNAs Reveals TLR-dependent and Independent Effects
    Journal of Molecular Biology, vol. 365, no. 1, pp. 90–108, 2007
  3. Connectivity can be used to identify key genes in DNA microarray data: a study based on gene expression in nasal polyps before and after treatment with glucocorticoids
    Acta Oto-Laryngologica, vol. 127, no. 10, pp. 1074–1079, 2007
  4. Photochemically Induced Gene Silencing Using Small Interfering RNA Molecules in Combination with Lipid Carriers
    Oligonucleotides, vol. 17, no. 2, pp. 166–173, 2007
  5. Comparison of hybridization-based and sequencing-based gene expression technologies on biological replicates
    BMC Genomics, vol. 8, no. 1, p. 153, 2007
  6. Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate
    BMC Genomics, vol. 8, no. 1, p. 273, 2007
  7. The Human Genomic Melting Map
    PLoS Computational Biology, vol. 3, no. 5, p. e93, 2007
  8. Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling
    Nucleic Acids Research, vol. 34, no. 3, pp. 996–1014, 2006
  9. Photochemically Induced Gene Silencing Using PNA-Peptide Conjugates
    Oligonucleotides, vol. 16, no. 2, pp. 145–157, 2006
  10. A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies
    Nature Biotechnology, vol. 24, no. 7, Article ID nbt1217, 8 pages, 2006
  11. Transcriptome changes in a colon adenocarcinoma cell line in response to photochemical treatment as used in photochemical internalisation (PCI)
    FEBS Letters, vol. 580, no. 24, pp. 5739–5746, 2006
  12. Gene-expression profiling in breast cancer
    The Lancet, vol. 365, no. 9460, pp. 634–635, 2005
  13. Response of malignant B lymphocytes to ionizing radiation: Gene expression and genotype
    International Journal of Cancer, vol. 115, no. 6, pp. 935–942, 2005
  14. Parallel nanoliter detection of cancer markers using polymer microchips
    Lab on a Chip, vol. 5, no. 4, p. 416, 2005
  15. Stitchprofiles.uio.no: analysis of partly melted DNA conformations using stitch profiles
    Nucleic Acids Research, vol. 33, no. Web Server, pp. W573–W576, 2005
  16. BMC Genomics, vol. 6, no. 1, p. 147, 2005
  17. BMC Genomics, vol. 5, no. 1, p. 10, 2004
  18. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study
    British Journal of Cancer, vol. 91, no. 10, Article ID 6602199, 5 pages, 2004
  19. The Detection of Hamster Connexins: A Comparison of Expression Profiles with Wild-Type Mouse and the Cancer-Prone Min Mouse
    Cell Communication & Adhesion, vol. 11, no. 5-6, pp. 155–171, 2004
  20. FigSearch: a figure legend indexing and classification system
    Bioinformatics, vol. 20, no. 16, pp. 2880–2882, 2004
  21. Analysis of the humoral immune response to immunoselected phage-displayed peptides by a microarray-based method
    PROTEOMICS, vol. 4, no. 9, pp. 2572–2582, 2004
  22. Double-sided silicon strip detectors: new applications within genomics and proteomics
    Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, vol. 527, no. 1-2, pp. 68–72, 2004
  23. Analytical Chemistry, vol. 76, no. 1, pp. 9–14, 2004
  24. Analytical Chemistry, vol. 76, no. 15, pp. 4406–4409, 2004
  25. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells
    Clinical & Experimental Metastasis, vol. 20, no. 8, pp. 701–711, 2003
  26. Speed-up of DNA melting algorithm with complete nearest neighbor properties
    Biopolymers, vol. 70, no. 3, pp. 364–376, 2003
  27. MGraph: graphical models for microarray data analysis
    Bioinformatics, vol. 19, no. 17, pp. 2210–2211, 2003
  28. Interferon-? suppresses S100A4 transcription independently of apoptosis or cell cycle arrest
    British Journal of Cancer, vol. 88, no. 12, Article ID 6600998, 6 pages, 2003
  29. BMC Bioinformatics, vol. 4, no. 1, p. 60, 2003
  30. BMC Genomics, vol. 4, no. 1, p. 11, 2003
  31. Analysis of repeatability in spotted cDNA microarrays
    Nucleic Acids Research, vol. 30, no. 14, pp. 3235–3244, 2002
  32. MArray: analysing single, replicated or reversed microarray experiments
    Bioinformatics, vol. 18, no. 8, pp. 1139–1140, 2002
  33. Associations between gene expressions in breast cancer and patient survival
    Human Genetics, vol. 111, no. 4-5, pp. 411–420, 2002
  34. The semantic web and biology
    Drug Discovery Today, vol. 7, no. 19, p. 992, 2002
  35. Nature Genetics, vol. 28, no. 1, pp. 21–28, 2001
  36. The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective series
    European Journal of Cancer, vol. 37, no. 8, pp. 1027–1032, 2001
  37. Genetic epidemiology of BRCA1 mutations in Norway
    European Journal of Cancer, vol. 37, no. 18, pp. 2428–2434, 2001
  38. Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: Gene expression profiles in bone marrow target cells
    International Journal of Cancer, vol. 97, no. 1, pp. 28–33, 2001
  39. CA 125: The End of the Beginning
    Tumor Biology, vol. 22, no. 6, pp. 345–347, 2001
  40. Penetrances of BRCA1 1675delA and 1135insA with Respect to Breast Cancer and Ovarian Cancer
    The American Journal of Human Genetics, vol. 65, no. 3, pp. 671–679, 1999
  41. Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53
    Human Genetics, vol. 104, no. 1, pp. 15–22, 1999
  42. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells
    International Journal of Cancer, vol. 80, no. 1, pp. 119–125, 1999
  43. Three per cent of Norwegian Ovarian Cancers are caused by BRCA1 1675delA or 1135insA
    European Journal of Cancer, vol. 35, no. 5, pp. 779–781, 1999
  44. Intracellular metabolism of a 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or asfree ribozyme. A study by capillary electrophoresis
    Nucleic Acids Research, vol. 26, no. 18, pp. 4241–4248, 1998
  45. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects
    Nucleic Acids Research, vol. 25, no. 1, pp. 151–157, 1997
  46. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
    European Journal of Cancer, vol. 33, no. 14, pp. 2390–2392, 1997
  47. Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein geneEGP-2
    International Journal of Cancer, vol. 72, no. 1, pp. 191–196, 1997
  48. Differential expression patterns ofS100a2, S100a4 andS100a6 during progression of human malignant melanoma
    International Journal of Cancer, vol. 74, no. 4, pp. 464–469, 1997
  49. CDKN2A (p16INK4A) somatic and germline mutations
    Human Mutation, vol. 7, no. 4, pp. 294–303, 1996
  50. Software and database for the analysis of mutations in the human FBN1 gene
    Nucleic Acids Research, vol. 24, no. 1, pp. 137–140, 1996
  51. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation
    Nucleic Acids Research, vol. 24, no. 1, pp. 141–146, 1996
  52. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains
    Genes, Chromosomes and Cancer, vol. 14, no. 1, pp. 71–75, 1995
  53. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection
    Human Mutation, vol. 5, no. 1, pp. 48–57, 1995
  54. Genome Scanning of Human Breast Carcinomas Using Micro- and Minisatellite Core Probes
    Genomics, vol. 17, no. 1, pp. 66–75, 1993
  55. Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE)
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 269, no. 1, pp. 41–47, 1992
  56. No alterations in exon 21 of theRBI gene in sarcomas and carcinomas of the breast, colon, and lung
    Genes, Chromosomes and Cancer, vol. 5, no. 2, pp. 97–103, 1992
  57. A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas
    Cancer Genetics and Cytogenetics, vol. 64, no. 2, pp. 178–182, 1992
  58. Detection of DNA variation in cancer
    Pharmacogenetics, vol. 2, no. 6, pp. 317–328, 1992
  59. Constant Denaturant Gel Electrophoresis as a Rapid Screening Technique for p53 Mutations
    Proceedings of the National Academy of Sciences, vol. 88, no. 19, pp. 8405–8409, 1991
  60. Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection Hovig, Eivind, Birgitte Smith-Sørensen, Anton Brøgger and Anne-Lisse Børresen (1991) Mutation Res., 262, 63–71
    Mutation Research Letters, vol. 263, no. 1, p. 61, 1991
  61. Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection
    Mutation Research Letters, vol. 262, no. 1, pp. 63–71, 1991
  62. Chromosome 13 alterations in osteosarcoma cell lines derived from a patient with previous retinoblastoma
    Cancer Genetics and Cytogenetics, vol. 57, no. 1, pp. 31–40, 1991
  63. Detection of base mutations in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 202, no. 1, pp. 77–83, 1988
  64. Chromosome 13 instability and esterase D expression in an osteosarcoma cell line
    Cancer Genetics and Cytogenetics, vol. 24, no. 2, pp. 327–334, 1987